"Rank","NCT Number","Title","Acronym","Status","Study Results","Conditions","Interventions","Outcome Measures","Sponsor/Collaborators","Gender","Age","Phases","Enrollment","Funded Bys","Study Type","Study Designs","Other IDs","Start Date","Primary Completion Date","Completion Date","First Posted","Results First Posted","Last Update Posted","Locations","Study Documents","URL"
1,"NCT04905836","Study of Allogeneic Adipose-Derived Mesenchymal Stem Cells for Treatment of COVID-19 Acute Respiratory Distress",,"Recruiting","No Results Available","Covid19","Biological: COVI-MSC|Drug: Placebo","All-cause mortality rate at Day 28|Incidence of all adverse events (AEs) (safety)|Incidence of treatment-emergent adverse events (safety)|Incidence of severe adverse events (safety)|Incidence of infusion-related adverse events (safety)|All-cause mortality rate at Day 60 and 90|Number of ventilator-free days through Day 28|Number of ICU days through Day 28|Change in clinical status|Change in oxygenation","Sorrento Therapeutics, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 2","60","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","MSC-COV-202","November 16, 2021","December 2022","March 2023","May 28, 2021",,"April 11, 2022","Teradan Clinical Trials LLC, Brandon, Florida, United States|Sarasota Memorial Health Care System (SMH), Sarasota, Florida, United States|St Luke's Research, Boise, Idaho, United States|St. Luke's Boise, Boise, Idaho, United States|Ascension St. John, Tulsa, Oklahoma, United States|PRX Research/Dallas Regional Medical Center, Mesquite, Texas, United States",,"https://ClinicalTrials.gov/show/NCT04905836"
2,"NCT04992247","Study of Allogeneic Adipose-Derived Mesenchymal Stem Cells to Treat Post COVID-19 ""Long Haul"" Pulmonary Compromise","BR","Not yet recruiting","No Results Available","Covid19","Biological: COVI-MSC|Biological: Placebo","Change in 6-Minute Walk Distance (6MWD) at Day 60|Change in 6MWD at Day 30|Relief of symptoms on Day 30 and Day 60|Change in Pulmonary Function|Change in oxygenation|Change in biomarker levels","Sorrento Therapeutics, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 2","60","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","MSC-PLH-201BR","November 2022","July 2023","September 2023","August 5, 2021",,"August 8, 2022",,,"https://ClinicalTrials.gov/show/NCT04992247"
3,"NCT04903327","Study of Intravenous COVI-MSC for Treatment of COVID-19-Induced Acute Respiratory Distress",,"Recruiting","No Results Available","Covid19","Biological: COVI-MSC|Drug: Placebo","All-cause mortality rate at Day 28|All-cause mortality rate at Day 60 and Day 90|Number of ventilator-free days through Day 28|Number of ICU days through Day 28|Change in clinical status|Change in oxygenation","Sorrento Therapeutics, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 2","100","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","MSC-COV-201BR","November 16, 2021","November 2022","March 2023","May 26, 2021",,"March 16, 2022","Hospital São Rafael S.A. - Instituto D'Or de Pesquisa e Ensino, Salvador, BA, Brazil|Santa Casa de Misericórdia da Bahia (Hospital Santa Izabel), Salvador, BA, Brazil|Saraiva & Berlinger Ltda. - EPP (IPECC), Campinas, SP, Brazil|CECIP JAU - Centro de Estudos Clínicos do Interior Paulista Ltda., Jaú, SP, Brazil|CEMEC - Centro Multidisciplinar de Estudos Clínicos Ltda. - EPP, São Bernardo Do Campo, SP, Brazil|Impar Serviços Hospitalares S/A (Hospital Nove de Julho), São Paulo, SP, Brazil",,"https://ClinicalTrials.gov/show/NCT04903327"
